Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.

Next Previous
X
Search
Trial Profile

An East Asian Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer; Medulloblastoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis

    • Most Recent Events

    • 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
    • 20 Apr 2016 Results of PK analysis of BOLT study and pooled analysis of other three studies including this published in the Journal of Clinical Pharmacology
    • 29 Aug 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top